Skip to main content

PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACYAND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMICLUPUS ERYTHEMATOSUS

Open
  • Protocol code: ZB012-02-001
  • EudraCT code: No aplica
  • Research group: Systemic Diseases
  • Service: Internal Medicine
  • Principal investigator:  Martínez Valle, Fernando
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II